© Profounda Pharmaceuticals

October 2, 2018

https://www.prnewswire.com/news-releases/fda-grants-profounda-inc-competitive-generic-therapy-cgt-designation-for-planned-anda-filing-of-minocycline-hydrochloride-microspheres1-mg-300719797.html

October 22, 2017

https://youtu.be/5KK0HYPK57c

December 31, 2016

Sales of Impavido, Rhinase Soothing Nasal Gel and Rhinase Lubricating Mist exceeded $2.5 M for 2016 making it a great start for Profounda as it looks to introduce new products to the market in 2017.

December 31, 2016

Orphan indication received by Profounda is for the treatment of Acanthamoeba Keratitis, also commonly known as AK usually associated with contact lens wear.

ORLANDO, Fla. 

December 16, 2016

Orphan indication received by Profounda is for the treatment of PAM, also commonly known as the Brain Eating Amoeba

ORLANDO, Fla. 

Dec  15, 2016  Profounda, Inc. ("Profounda") announced today that it has received, the US Food and Drug Administration’s (FDA) Orphan Drug...